login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
FULCRUM THERAPEUTICS INC (FULC) Stock News
NASDAQ:FULC -
US3596161097
-
Common Stock
6.88
USD
+0.36 (+5.52%)
Last: 8/22/2025, 8:11:08 PM
6.88
USD
0 (0%)
After Hours:
8/22/2025, 8:11:08 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FULC Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 days ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 days ago - By: Benzinga
- Mentions:
STX
CAR
EDU
TAL
...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
a month ago - By: Benzinga
- Mentions:
EXEL
HLIT
VRSN
NVO
...
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
3 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Participate in Upcoming May Conferences
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
4 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
5 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
6 months ago - By: Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Please enable JavaScript to continue using this application.